MADE IN CANADA: THE STORY OF VYXEOS

canada_formulation

Formulated to optimize the synergistic activity of daunorubicin and cytarabine

canada_designed

Designed using the CombiPlex® Platform by Celator Pharmaceuticals in Vancouver, BC (now a subsidiary of Jazz Pharmaceuticals)

canada_tested

Tested in pre-clinical and clinical trials across multiple Canadian sites

BC: British Columbia

Reference: Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692.

CA-VYX-2400010-E | March 2024